Caliway Biopharmaceuticals Co., Ltd. Overview
Pro stress-test →Caliway Biopharmaceuticals is specialized in the development of new drugs for medical aesthetic and inflammatory disease. The company focuses on innovative small-molecule therapeutics targeting underserved aesthetic and metabolic health markets, with lead candidate CBL-514 now advancing into Phase 2 U.S. clinical trials for weight management in combination with GLP-1RA therapies.
Strategic Profile
Pro stress-test →CBL-514, Caliway's leading product, is expected to effectively reduce subcutaneous fat precisely at the injection site by causing targeted adipocyte apoptosis without damaging other tissues and cells. The company has completed FDA IND submission for Phase 2 clinical studies, accelerating development in combination with GLP-1R agonist therapies and expanding the company's R&D footprint in the global weight management field.
Competitive Landscape
Pro stress-test →Caliway competes in the aesthetic pharmaceutical and weight management markets against larger players developing novel fat reduction and skin rejuvenation treatments. Key competitive dynamics include GLP-1 agonist combination approaches and non-invasive aesthetic medicine therapies. The company's first-in-class positioning for localized fat reduction differentiates it from systemic weight loss approaches, though it faces competition from established aesthetics companies and emerging biotech players.
Industry Context
Caliway Biopharmaceuticals Co., Ltd. operates in Biopharmaceuticals - Aesthetic Medicine & Metabolic Health.
Key facts
Founded: 2012 · Headquarters: New Taipei City, Taiwan · Revenue: $44.4M (2024) · Market cap: $9.2B TWD (~$229.55B reported in local currency units)